Feasibility and Safety of the Preemie Orthotic Device to Manage Deformational Plagiocephaly in Extremely Low Birth Weight Infants.


Journal

Advances in neonatal care : official journal of the National Association of Neonatal Nurses
ISSN: 1536-0911
Titre abrégé: Adv Neonatal Care
Pays: United States
ID NLM: 101125644

Informations de publication

Date de publication:
Jun 2019
Historique:
pubmed: 7 2 2019
medline: 25 12 2019
entrez: 7 2 2019
Statut: ppublish

Résumé

Premature infants are predisposed to developing deformational plagiocephaly. Deformational plagiocephaly may affect the infant's social well-being and neurobehavioral development. This pilot study investigated the feasibility and safety of the preemie orthotic device (POD); a noncommercial, supportive orthotic device to manage deformational plagiocephaly. The setting for this prospective, descriptive, phase 1 clinical trial was 2 urban and 1 suburban neonatal intensive care units that provided care for critically ill premature and term infants. Participants included a convenience sample of 10 premature extremely low-birth-weight infants weighing less than 1 kg. All participants received the experimental treatment with the POD. Time spent on the device with and without the supportive foam insert, provider perception, adverse events, and head shape measurements were collected to assess feasibility and safety of the device. Participants had a median gestational age of 25.4 weeks and median birth weight of 0.673 kg. The POD was used a median of 21.2 hours per day and the foam insert was used a median of 11.1 hours per day. At enrollment, 1 participant had a normal cranial index compared with 5 participants at study completion. All participants had normal cranial symmetry at study enrollment and completion. No device-related adverse events were reported. The POD was found to be feasible and safe. Staff had favorable responses to the device. Recommendations by nursing staff included enlarging the device to extend its use. Further studies are warranted to assess the POD's effectiveness.

Sections du résumé

BACKGROUND BACKGROUND
Premature infants are predisposed to developing deformational plagiocephaly. Deformational plagiocephaly may affect the infant's social well-being and neurobehavioral development.
PURPOSE OBJECTIVE
This pilot study investigated the feasibility and safety of the preemie orthotic device (POD); a noncommercial, supportive orthotic device to manage deformational plagiocephaly.
METHODS METHODS
The setting for this prospective, descriptive, phase 1 clinical trial was 2 urban and 1 suburban neonatal intensive care units that provided care for critically ill premature and term infants. Participants included a convenience sample of 10 premature extremely low-birth-weight infants weighing less than 1 kg. All participants received the experimental treatment with the POD. Time spent on the device with and without the supportive foam insert, provider perception, adverse events, and head shape measurements were collected to assess feasibility and safety of the device.
RESULTS RESULTS
Participants had a median gestational age of 25.4 weeks and median birth weight of 0.673 kg. The POD was used a median of 21.2 hours per day and the foam insert was used a median of 11.1 hours per day. At enrollment, 1 participant had a normal cranial index compared with 5 participants at study completion. All participants had normal cranial symmetry at study enrollment and completion. No device-related adverse events were reported.
IMPLICATION FOR PRACTICE CONCLUSIONS
The POD was found to be feasible and safe. Staff had favorable responses to the device. Recommendations by nursing staff included enlarging the device to extend its use.
IMPLICATION FOR RESEARCH CONCLUSIONS
Further studies are warranted to assess the POD's effectiveness.

Identifiants

pubmed: 30724785
doi: 10.1097/ANC.0000000000000585
doi:

Types de publication

Clinical Trial, Phase I Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

226-235

Auteurs

Aimee Knorr (A)

Department of Pediatrics, Harvard Medical School, Boston, Massachusetts (Drs Knorr, Gauvreau, DeGrazia); Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, Massachusetts (Dr. Gauvreau); Division of Newborn Medicine (Dr. Knorr), Cardiovascular and Critical Care Services (Ms Porter and Serino, Dr DeGrazia), Department of Cardiology (Dr. Gauvreau), Boston Children's Hospital, Boston, Massachusetts; Division of Newborn Medicine, Winchester Hospital, Winchester, Massachusetts (Dr. Knorr); Department of Nursing, Brigham and Woman's Hospital, Boston, Massachusetts (Dr. Giambanco); Department of Nursing, St. Elizabeth's Medical Center, Brighton, Massachusetts (Ms Staude); Department of Medicine, U-Mass Memorial Medical Center, Worchester, Massachusetts (Ms St. Germain).

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH